Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Monopar Therapeutics

NASDAQ: MNPR · Life Sciences · 5 alerts · CIK 1645469

Share price
$71.97Close, Nov 16
Market cap
$488M
Shares outstanding
6.78MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Monopar Therapeutics filings on SEC EDGAR ↗

8:01 AM ET 8-K
Financial Results

Monopar Therapeutics Financial Results

Monopar Therapeutics reported third quarter 2026 financial results, including a net loss of $6.2 million and a cash position of $129.4 million. The company highlighted progress on its rolling NDA submission for ALXN1840 in Wilson disease, which it expects to complete within the next several weeks.

8:01 AM ET 10-Q
Financial Results

Monopar Therapeutics Q3 2026 Results: Net Loss of $6.2M, Loss Widens

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on radiopharmaceuticals and copper-chelating therapies like ALXN1840. For the nine months ended September 30, 2026, the company reported 6,776,773 shares of common stock outstanding and continues to incur significant losses as it prepares a rolling NDA submission for ALXN1840.

Key figure
Net loss $6.2M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.